News

Blue Earth Diagnostics Announces Efficacy and Safety Results from Phase 3 LIGHTHOUSE Trial of Investigational PET Imaging Agent ¹⁸F-rhPSMA-7.3 in Newly Diagnosed Prostate Cancer

View more

Dec 05, 2022

Ga-68 PSMA-11 changes management in most prostate cancer cases

View more

Dec 02, 2022

Study: Pylarify PET/MRI may help identify candidates for focal ablative therapy

View more

Dec 02, 2022

Full-Life Technologies to Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipeline

View more

Dec 02, 2022

NNSA partner NorthStar Medical Radioisotopes completes construction and equipment installation for new molybdenum-99 production facility

View more

Nov 30, 2022

Crucial cancer scans cancelled due to global isotope shortage

View more

Nov 28, 2022